Our services
Request an appointment
Reserve your spot with our medical team in just minutes.
If stubborn abdominal fat has not responded to diet or exercise, the problem may be hormonal rather than your lifestyle. Medical Cosmetic Enhancements, serving Washington, DC, Northern Virginia, and the Maryland suburbs since 2003, offers Tesamorelin therapy as part of a physician-supervised peptide optimization program.
Part of the very small number of peptides that have been approved by the FDA for human therapeutic use, Tesamorelin is capable of targeting visceral fat – the deep abdominal fat that wraps around organs and resists even disciplined diet and exercise.
What Is Tesamorelin?
Tesamorelin works differently than you might expect from peptide therapy. Instead of injecting growth hormone directly into your body, this FDA-approved peptide gently tells your pituitary gland to produce its own growth hormone – on your body’s natural schedule. The result feels more balanced because your body’s own rhythms stay in control.
The FDA approved Tesamorelin back in 2010 as Egrifta, specifically for reducing stubborn belly fat in people with HIV-related lipodystrophy. However, its powerful visceral fat-reduction ability has also made it attractive for people hoping to trim their body shape.
FDA approval means Tesamorelin has been thoroughly tested and undergone multiple clinical trials to make sure that it’s safe for human use and, as a result, isn’t one of the countless unregulated peptides you find online.
The Clinical Evidence
The pivotal clinical trial by Falutz et al., published in the New England Journal of Medicine, demonstrated roughly a 15–20% reduction in visceral adipose tissue (VAT) over 6-12 months. A follow-up study confirmed reductions were sustained over 52 weeks of continuous therapy, and that visceral fat tended to reaccumulate after discontinuation, which supports ongoing or cyclical use for patients who want maintained results.
Several extra benefits have also been observed across those clinical trials, including:
- Improved lipid profiles
- Enhanced insulin sensitivity and glucose metabolism
- Increased lean body mass alongside fat reduction
Cognitive benefits – improved memory and executive function reported in some trials (Alzheimers & Dementia Journal).
Why Visceral Fat Is Different
Not all body fat carries the same metabolic risk. Subcutaneous fat sits just below the skin and responds reasonably well to calorie restriction. Visceral fat wraps around the liver, pancreas, and intestines. Research consistently links excess visceral fat to elevated cardiovascular risk, insulin resistance, and chronic inflammation (Frontiers in Endocrinology). It is also uniquely resistant to many weight-loss strategies.
Tesamorelin’s mechanism targets this specific deposit. By restoring more youthful GH secretion, it shifts fat metabolism preferentially toward the visceral compartment while leaving lean tissue largely untouched. General weight loss programs usually don’t have such precision.
How Tesamorelin Compares to Other Fat Reduction Options
|
Approach
|
Targets Visceral Fat
|
Non-Invasive
|
Preserves Lean Mass
|
FDA Status
|
|---|---|---|---|---|
|
Tesamorelin |
(primary target) |
Yes |
Yes |
FDA-Approved (off-label use in wellness) |
|
Liposuction |
Subcutaneous only |
No |
Yes |
FDA-cleared device |
|
CoolSculpting Elite |
Subcutaneous only |
Yes |
Yes |
FDA-cleared |
|
Semaglutide (GLP-1) |
Both (nonspecific) |
Yes |
Variable |
FDA-Approved |
|
Direct HGH Injections |
Yes |
Yes |
Yes |
FDA-Approved (narrow indications) |
How It Pairs with Other Services at Medical Cosmetic Enhancements
Tesamorelin addresses the deep metabolic picture while our in-office procedures refine body contour.
Patients often combine it with liposuction and laser liposuction for subcutaneous fat, CoolSculpting Elite for non-surgical spot reduction, or CoolTone for muscle definition.
For patients managing weight medically, Tesamorelin pairs well with our semaglutide weight loss program – the GLP-1 drives the caloric deficit while Tesamorelin specifically targets visceral fat and protects lean mass.
Frequently Asked Questions
No. Tesamorelin signals your own pituitary to release growth hormone naturally, preserving your body's feedback systems. Direct HGH injections bypass this mechanism and can suppress natural production over time.
The FDA-approved indication covers HIV-associated lipodystrophy. Off-label prescribing for visceral fat reduction in other patients is legal and widely practiced in functional medicine. Patients should understand this context before starting.
Clinical trials showed measurable VAT reduction within 8–12 weeks and significant results by week 26. Many patients notice changes in abdominal fullness earlier, particularly when combined with dietary adjustments.
Studies confirm that visceral fat tends to gradually reaccumulate after discontinuation. Many patients continue a maintenance dose or use cyclical therapy to sustain results.
Coverage for off-label use is rare. Our team will review self-pay options and package pricing during your consultation.
Take the Next Step
Among the many peptides marketed for fat loss and body composition, Tesamorelin is one of the very few backed by genuine FDA approval and Phase 3 clinical trial data. At Medical Cosmetic Enhancements, we prescribe only FDA-approved peptides and legally compoundable compounds through licensed pharmacies. Your safety and our medical integrity are non-negotiable.
Call (202) 621-8675 or request an appointment online at our Washington, DC office between Georgetown and Dupont Circle.